Background
Bone remodeling is one of the earliest tissues to accumulate senescent cells with aging, particularly senescent osteoclasts. These cells adopt a robust senescence-associated secretory phenotype (SASP). Independently, extracellular vesicles (EVs) are recognized as systemic mediators of intercellular signaling. However, the role of senescent osteoclast-derived EVs as vectors of systemic inflammaging remains unexplored.
Hypothesis
Senescent osteoclasts release EVs enriched in activated NF-κB subunits (p65/RelA), miR-21-5p, and HMGB1 that are taken up by distal tissues (adipose, liver, vascular endothelium), where they activate resident macrophage NF-κB signaling and amplify local SASP independent of local senescence burden. This creates a bone-to-periphery inflammaging axis in which skeletal senescence disproportionately drives systemic chronic inflammation.
Testable Predictions
- In vitro: EVs isolated from senolytic-resistant senescent osteoclasts (induced by irradiation or serial passage) will contain significantly higher levels of p65, miR-21-5p, and HMGB1 compared to EVs from proliferating osteoclasts, quantifiable by Western blot and small RNA-seq.
- Transfer experiment: Co-culture of senescent osteoclast-conditioned EVs with naïve adipose tissue macrophages will upregulate IL-6, TNF-α, and MCP-1 secretion within 48h, abolishable by EV depletion (GW4869) or NF-κB inhibition (BAY 11-7082).
- In vivo: Young mice injected with senescent osteoclast EVs will show elevated circulating IL-6 and hepatic NF-κB activation at 2 we





























